Esophageal cancer secondary prevention
|
Esophageal cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Esophageal cancer secondary prevention On the Web |
|
American Roentgen Ray Society Images of Esophageal cancer secondary prevention |
|
Risk calculators and risk factors for Esophageal cancer secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]
Overview
Secondary prevention may be effective in reducing the incidence of esophageal cancer, if treated early at the dysplasia stage with monoclonal antibody therapy. At present, there is no particular program in place to reduce the incidence of esophageal cancer.
Secondary Prevention
Secondary prevention can be effective in high risk groups who frequently smoke and drink alcohol if they are treated (with monoclonal antibodies) early enough in the dysplastic phase before cancer occurs.[1]
- A study was carried out in Hishun village, China in patients with advanced esophageal dysplasia who were treated with monoclonal antibodies and subsequently showed a reduction in the incidence of esophageal cancer by 53%.
- Due to different dietary factors, the incidence of esophageal cancer among these people was particularly high.
- Subjects were examined by esophageal exfoliative cytology.
- One third of the participants had marked dysplasia.
- They were placed on a antitumor B regimen for 3 years.
- The incidence of esophageal cancer in the antitumor B group was reduced by 53%.
- These results demonstrated the effectiveness of secondary prevention in the prevention of esophageal cancer.